Compare Biogen Inc (BIIB) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Illinois Tool Works Inc. — how do they compare? Biogen Inc trades at $205.9 (market cap $30.13B), while Illinois Tool Works Inc. trades at $292.76 (market cap $83.49B). The key difference: Illinois Tool Works Inc. is far larger — about 2.8× Biogen Inc's market cap, and Illinois Tool Works Inc. pays a 2.35% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | ITW | |
|---|---|---|
Market Cap | $30.13B | $83.49B |
Sector | Health | Industrials |
52-Week High | $216.63 | $299.60 |
52-Week Low | $128.93 | $241.07 |
Enterprise Value | $37.20B | $92.34B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
ITW trades at $294.52, down 0.72% today, with bullish technical signals from moving averages and a consensus price target of $314.25 representing 6.7% upside. The company has beaten earnings estimates for three consecutive quarters, maintains strong profitability with 19.39% net margins, and recently announced a 7% dividend increase alongside a $6 billion share repurchase program. Revenue remains stable around $16 billion annually with consistent cash flow generation.
The outlook remains positive given strong operational execution and shareholder returns, though valuation multiples appear elevated with a P/E of 26.55. Key risks include potential margin pressure from economic cycles and high debt levels at 55.54% of assets. The stock offers quality exposure to industrial recovery with disciplined capital allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
